We have built up an exciting portfolio of investments in high potential businesses across a range of therapeutic areas, technologies, geographies and clinical contexts.
08 August 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended June 30, 2018 and provided an update on its development programs.
07 August 2018
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2018 . In addition, the Company provided a clinical and business update. As of June 30, 2018 , Syndax had $98.4 million in cash, cash equivalents and short-term investments.